The Open Hematology Journal

2008, 2 : 25-29
Published online 2008 April 11. DOI: 10.2174/1874276900802010025
Publisher ID: TOHJ-2-25

Clinical Evaluation of Platelet Concentrates Either in Plasma or in Additive Solution

Luis Larrea , Nelly Carpio , Cristina Arbona , María Angeles Soler , Javier de la Rubia and Roberto Roig
Centro de Transfusión de la Comunidad Valenciana, Avda del Cid 65, 46014 Valencia, Spain.

ABSTRACT

Background and Objectives. Platelet concentrates (PC) obtained from Buffy-Coat (BC) may be diluted in a platelet additive solution (PAS). These PCs may reduce plasma-related adverse reactions. We have tried to assess the relationship between PAS PCs and adverse reactions. Materials and Methods. During 6 months, patients treated with intensive chemotherapy, participated in a prospective study and were randomly assigned to receive, on a prophylactic basis, PCs in either plasma or PAS-2. Five iso-group BCs were pooled diluted in either plasma or PAS-2. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded. Results. Platelet increment, 1-hour platelet count, and corrected count increments (CCI) after transfusion in both groups were similar. There were more transfusion- dependent adverse reactions in plasma group. Conclusion. Use of PAS-2 resulted in less transfusion related reactions; therefore, we recommend synthetic additive solutions to dilute PCs.

Keywords:

Platelet transfusions, PAS, Adverse reactions.